MTARC1 p.A165 ablation reduces hepatocellular carcinoma aggressiveness in vitro and in vivo | Synapse
February 8, 2026Open Access
MTARC1 p.A165 ablation reduces hepatocellular carcinoma aggressiveness in vitro and in vivo
Key Points
The study aims to investigate the effects of MTARC1 p.A165 ablation on hepatocellular carcinoma aggressiveness.
In vitro experiments assessing lipid accumulation and tumor-promoting pathways.
In vivo studies to evaluate tumor growth dynamics after MTARC1 p.A165 downregulation.
MTARC1 p.A165 ablation decreases lipid accumulation in liver cells.
This downregulation dampens pathways that promote tumors.
Tumor growth is significantly restricted in both in vitro and in vivo models.
Abstract
Downregulation of MTARC1 p.A165 inhibits lipid accumulation, dampens tumor-promoting pathways and restricts tumor growth, highlighting MTARC1 as a promising therapeutic target for HCC.